Masahiro Torasawa, Medical Oncologist at Juntendo University, shared a post on X:
“Brain-Only Progression After 1L Therapy in ES-SCLC.
For brain-only progression in ES-SCLC, continuing the original systemic therapy with brain radiotherapy may yield better survival than switching regimens.”
Title: Brain-Only Progression After First-Line Therapy in Extensive-Stage Small Cell Lung Cancer: Treat the Sanctuary, Preserve the Backbone
Authors: Yuchen Li, Lilian Faroni, Fabio Ynoe Moraes
You can also read:
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
